Top Tweets for #Relacorilant
🙌Platinum‑resistant #OvarianCancer has an OS signal worth celebrating.
Dr. Olawaiye (@UPMC) discusses his #ASCO26-presented data showing #relacorilant+nab‑paclitaxel delivers a 35% reduction in death.
This isn’t incremental. It’s disruptive👉️https://t.co/ZxjEmJpnfx
#OncDocs
#ROSELLA at #ASCO26: #relacorilant + nab-paclitaxel improved OS in #platinum_resistant #ovariancancer (HR 0.65, 0.51–0.83).
The interesting part: the benefit held even in patients who had taxane as their last prior regimen. This is not re-challenging with the same drug and hoping for the best - GR blockade appears to mechanistically restore taxane sensitivity.
I call it> Taxol after Taxol, but with a reason!
@ASCO
#SGOAM2026 #Recap
今年3月にFDA承認された #Relacorilant がとても印象的でした。SGOプレジデントのスピーチ直後の発表で、会場の注目度も高かったです。
Relacorilant は 選択的グルココルチコイド受容体アンタゴニスト。
PROCに対する relacorilant + nab-paclitaxel は、#ROSELLA study
PFS 6.5 vs 5.5か月（HR 0.70）
OS 16.0 vs 11.9か月（HR 0.65）
と、かなりインパクトのある結果でした。
mirvetuximab のようなFRα陽性例に限られる治療とは別軸で、PROCの治療選択肢が広がるのは大きいと思いました。
Updates from #SGO26: Final #OS results from the phase 3 #ROSELLA trial demonstrate that the addition of #relacorilant to nab-#paclitaxel significantly improves survival in platinum-resistant #ovarian cancer. Learn more: https://t.co/yKTySPwVHs
#medtwitter #onctwitter
ROSELLA First Phase 3 win targe full analysis, treatment sequencing & what this means →https://t.co/YXzeOEJpOz
#OvarianCancer #GynOnc #ROSELLA #ClinicalTrials #Oncology #MedTwitter #OncTwitter #PROC #Relacorilant @brunolarvol @OncoAlert @OncLive @oncodaily @Corcept
Patients with endogenous #hypercortisolism of various causes given #relacorilant during the randomised-withdrawal phase were 5·9 times more likely to maintain #hypertension response compared with those who received placebo https://t.co/LgoRUn7Z5o
#Cushing's syndrome
✅ The combination of #relacorilant ➕ #Abraxane has been approved by the #FDA for adults with certain platinum-resistant #OvarianCancer
Data from the phase 3 ROSELLA trial showed a 3️⃣0️⃣% improvement in median PFS compared with nab-paclitaxel monotherapy https://t.co/HJLJ9AGAkU
The FDA just changed how we sequence
Platinum Resistant #OvarianCancer . Yesterday’s approval of #Relacorilant (Lifyorli) + nab-
#paclitaxel (March 25, 2026) moves us past "chemo-switching" and into Resistance-Modulating. The utility here is pure biology: we’re finally targeting the Glucocorticoid Receptor (GR) "stress shield" to re-sensitize the tumor to the taxane. The #ROSELLA trial data speaks for itself: 35% reduction in risk of death (HR 0.65). OS: 16.0 mo vs 11.9 mo. 1–3 prior lines, including Bev. No biomarker needed!
☑️Dismantling GR signaling works across the board.
>>Between this and the Feb 10 FDA approval of #Pembrolizumab/#paclitaxel (#KEYNOTEB96) for PD-L1+ cases, our 2026 algorithm is finally specialized:
1- Hit the PD-1 for immune evasion.
2- Hit the GR for stress evasion.
This data published in @TheLancet is the blueprint for the next generation of PROC sequencing.
@GOG @ESGO_society @ENYGO_official @OncoAlert @GynMe4
🆕 #FDA clears combination of Corcept Therapeutics’ #relacorilant ➕ @BMSNews’ #Abraxane for adults with platinum-resistant ovarian, fallopian tube and peritoneal cancers
📊 Combo therapy improves PFS and OS 🆚 Abraxane alone https://t.co/dZcgJeyOaR
In the April Issue:
Efficacy and safety of #relacorilant for the treatment of patients with #Cushing's syndrome (GRACE): a multicentre, phase 3, double-blind, placebo-controlled, randomised-withdrawal study https://t.co/LgoRUn7Z5o
#endogenous #hypercortisolism
Patients with endogenous #hypercortisolism of various causes given #relacorilant during the randomised-withdrawal phase were 5·9 times more likely to maintain #hypertension response compared with those who received placebo https://t.co/LgoRUn7Z5o
#Cushing's syndrome
Patients with endogenous #hypercortisolism of various causes given #relacorilant during the randomised-withdrawal phase were 5·9 times more likely to maintain #hypertension response compared with those who received placebo https://t.co/LgoRUn7Z5o
#Cushing's syndrome
Also read the Linked Comment:
Specific cortisol blockade in Cushing's syndrome https://t.co/SofSCKBWFk
#Cushing's syndrome #relacorilant
Online—Efficacy and safety of #relacorilant for the treatment of patients with Cushing's syndrome (GRACE): a multicentre, phase 3, double-blind, placebo-controlled, randomised-withdrawal study https://t.co/LgoRUn7Z5o
#Cushing's syndrome
🔬 #ClinicalTrialNews: The ROSELLA trial reveals #relacorilant plus nab-paclitaxel significantly improves survival in platinum-resistant #OvarianCancer without increasing safety risks.
⭐ 4.1-month median OS boost: 16.0 months vs 11.9 months ⭐
https://t.co/kWfrx8vLus
🎙️ New #IJGCConversations!
@pedroramirezMD speaks with Dr. Alexander B. Olawaiye 🇺🇸 about the #ROSELLA Trial exploring #Relacorilant in Platinum Resistant #OvarianCancer 💊🎗️
🎧 Listen now 🌍
🔗 https://t.co/oUPzxOhM5F
@HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @RParejaGineOnco @lchiv4 @annafagottimd @HousseinELHAJJ3 @AinhoaMada @MathildeDel2 @DrPervan @T_Meschini @moe_byrneMD @MatteoLoverro @CSabiniMD @ZaniruRaul
#WeeklyPodcast #IJGConline #Research #Treatment #Diagnostic #GynCancer #GynOnc #WomenHealth #SoMe #SoMe4GynOnc
@SuyogCancer @Esmo Shattering Ceilings: New Healing in #OvarianCancer! Platinum resistance isn’t a wall—it’s a window to new hope.
🪟 #Relacorilant (glucocorticoid antagonist) helps re-sensitize chemo.
📷 Precision leads when resistance rewrites the rules.
🌟 Shattering Ceilings: New Healing in #OvarianCancer!
Platinum resistance isn’t a wall—it’s a window to new hope. 🪟
#Relacorilant (glucocorticoid antagonist) helps re-sensitize chemo.
🎯 Precision leads when resistance rewrites the rules.
🔗 @UPMCHillmanCC @ASCO #ASCO25 #gynsm
🌟 Shattering Ceilings: New Healing in #OvarianCancer!
Platinum resistance isn’t a wall—it’s a window to new hope. 🪟
#Relacorilant (glucocorticoid antagonist) helps re-sensitize chemo.
🎯 Precision leads when resistance rewrites the rules.
🔗 @UPMCHillmanCC @ASCO #ASCO25 #gynsm
🧬 Platinum resistance isn't the end — it's the beginning of new strategies.
A selective glucocorticoid receptor antagonist #relacorilant shows promise in shifting the standard for platinum-resistant #ovariancancer
⚙️ Cortisol blockade = chemo re-sensitization
Precision matters — especially when resistance rewrites the rules.
🔗 @UPMCHillmanCC @ASCO
#ASCO25 #gynsm
Last Seen Hashtags on Sotwe
นครสวรรค์
ometv
Seen from Brazil
snapchat
Seen from Philippines
JenniferWhite
Seen from Mexico
legionseven
Seen from United States
memeulous
Seen from South Africa
ebonyshemales
Seen from Austria
เย็ดนักเรียน
Seen from Thailand
yangzongbao
Seen from United States
teenageee() +filter:videos
Seen from Spain
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
241.7M followers
Barack Obama
@barackobama
119M followers
Cristiano Ronaldo
@cristiano
114.6M followers
Donald J. Trump
@realdonaldtrump
111.9M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90.1M followers
Taylor Swift
@taylorswift13
84M followers
Lady Gaga
@ladygaga
75.5M followers
Virat Kohli
@imvkohli
73.5M followers
Kim Kardashian
@kimkardashian
70.9M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.5M followers
Bill Gates
@billgates
65.2M followers
Selena Gomez
@selenagomez
63.1M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers